Cybrexa Therapeutics Inc

Changing the paradigm for cancer treatment through the development of antigen-independent peptide drug conjugates.
CGs:

[Cybrexa Therapeutics Inc @Cybrexa]

Meet Cybrexa’s leadership team built on deep experience in oncology drug development, clinical trials, and company growth. Together, we are developing the next generation of cancer therapeutics and advancing the future of cancer treatment. https://t.co/iAnzZ6iPEH

[Cybrexa Therapeutics Inc @Cybrexa]

Cybrexa’s alphalex™- enabled peptide-drug conjugates bypass traditional therapy limits by targeting universal tumor biology. Our antigen-agnostic approach means more patients with cancer may benefit from treatment, regardless of specific tumor markers. https://t.co/mcEneseAh4

[Cybrexa Therapeutics Inc @Cybrexa]

Cybrexa Therapeutics presented new preclinical data at #ESMOTAT25 showing alphalex™ peptide-drug conjugates achieved robust efficacy across multiple tumor models, both as monotherapy and in combination with standard treatments. Read the full results here: https://t.co/b7xVBwxs3p

[Cybrexa Therapeutics Inc @Cybrexa]

Cybrexa will present new preclinical findings at #ESMOTAT25 on the potential of alphalex™ peptide-drug conjugates to achieve tumor-selective delivery while minimizing off-target effects.

📅 March 3 | ⏰ 5:15-6:15 PM CET | 🎤 Vishwas Paralkar, Ph.D.
https://t.co/FF5t82FTWT

[Cybrexa Therapeutics Inc @Cybrexa]

In a robust Phase 1 trial, our lead clinical-stage program, CBX-12, showed compelling safety & efficacy across six tumor types. With activity confirmed, even in heavily pretreated patients, we are advancing CBX-12 into Phase 2 trials. https://t.co/UkukqrSwRK
#biotech

[Cybrexa Therapeutics Inc @Cybrexa]

Our alphalex™ tumor-targeting peptide platform leverages the acidic microenvironment found in all solid tumors, enabling precise delivery of potent therapies where they’re needed most. Explore our science: https://t.co/mcEneseAh4

#biotech

[Cybrexa Therapeutics Inc @Cybrexa]

Just announced: The first patient has been dosed with CBX-12 in a Phase 2 trial in women with platinum-resistant or refractory #ovariancancer who are naïve to TOP1-targeted therapies. Learn more at https://t.co/8AQ9956zpj. #biotech #oncology #clinicaltrials

[Cybrexa Therapeutics Inc @Cybrexa]

We announced final results from our Phase 1 study of CBX-12 in advanced solid tumors, which showed broad activity across 6 tumor types, including strong response rates in TOP1-naive patients with ovarian and breast #cancer.

Read more: https://t.co/XlFdkkRktW #ESMO24 #biotech

[Cybrexa Therapeutics Inc @Cybrexa]

We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at @myESMO.

Join us at 12pm CET on Sept 14 to learn more: https://t.co/JThLIyNsb9
#oncology #ESMO24 #biotech

[Cybrexa Therapeutics Inc @Cybrexa]

#Cybrexa is revolutionizing #cancertherapeutics with its innovative alphalex™ platform, aiming to deliver drugs directly into cancer cells. Stay tuned for exciting clinical updates. https://t.co/1ptR6511FQ.

#peptidedrugconjugates #oncology

[Cybrexa Therapeutics Inc @Cybrexa]

#DYK, Cybrexa's scientists are pioneering #cancertherapeutics to target tumors & spare healthy tissue? Our approach aims to enhance current therapies & pave the way for new ones. 👉 https://t.co/DyME1UBqlt.

#drugdiscovery #smallmolecules #peptidedrugconjugates #WeAreCybrexa

[Cybrexa Therapeutics Inc @Cybrexa]

Happy #IndependenceDay! Today we are celebrating the freedom made possible by our brave heroes.

#FourthofJuly #WeAreCybrexa

[Cybrexa Therapeutics Inc @Cybrexa]

#NEWS: Cybrexa Therapeutics today announced the appt. of former founding Alnylam CEO, @JMaraganore, as Strategic Advisor to the Exec. Leadership Team. Full release: https://t.co/koshJpSEea.

#drugdiscovery #smallmolecules #peptidedrugconjugates #CTBiotech #WeAreCybrexa

[Cybrexa Therapeutics Inc @Cybrexa]

#DYK: #Cybrexa & most of our team are HQ’d in #CT, but some of us live in FL, GA, MA, NH, NJ, RI & TX. Despite the distance, Cybrexa’s commitment to raising awareness for various cancers unites our team. Last month, we wore teal ribbons on #WorldOvarianCancerDay. Check us out 👇!

[Cybrexa Therapeutics Inc @Cybrexa]

On this #MemorialDay, we remember those who gave their lives for our freedom. We wish everyone a safe & meaningful Memorial Day weekend. #MDW24

[Cybrexa Therapeutics Inc @Cybrexa]

At #Cybrexa, we're working to revolutionize #cancertherapeutics by leveraging our alphalex™ technology to develop novel & innovative anti-cancer agents. https://t.co/1ptR650tQi.

#drugdiscovery #smallmolecules #peptidedrugconjugates

[Cybrexa Therapeutics Inc @Cybrexa]

Join us at the ADC Payload Summit in Boston next week for a discussion on #Cybrexa's tumor-selective alphalex™ platform by our CSO Vish Paralkar. Check out the conference agenda here 👉: https://t.co/WTjJgYsiWB.

[Cybrexa Therapeutics Inc @Cybrexa]

Today is #WorldOvarianCancerDay. Early detection is key. Check out the resources below to learn more. Let's spread awareness and make a difference in the fight against #ovariancancer. #earlydetection #getscreened

[Target Ovarian Cancer @TargetOvarian]

Today is #WorldOvarianCancerDay. Do you know the symptoms of #ovariancancer?

Repost our video to help spread the word and raise vital awareness. For more information about ovarian cancer symptoms, visit our website 👉 https://t.co/KCPIEJRsjh

#NoWomanLeftBehind #WOCD2024

[Cybrexa Therapeutics Inc @Cybrexa]

Meet Lindsey Clapes, Office Manager at #Cybrexa. W/ 10+ yrs exp in biotech/pharma, Lindsey oversees the travel program, organizes team events, leads community outreach & keeps track of the boss. She enjoys the startup environment & progression of science. #EmployeeSpotlight

[Cybrexa Therapeutics Inc @Cybrexa]

Happy #WorldLaboratoryDay! At Cybrexa, our lab team is working hard to develop new #cancertherapeutics with the potential to improve pts' lives. Learn about our mission & the incredible work we are doing to transform the future of #oncolgy 👉 https://t.co/V262bvnOIi.